MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
16.66
-0.19 (-1.13%)
At close: Apr 28, 2026, 4:00 PM EDT
16.76
+0.10 (0.59%)
After-hours: Apr 28, 2026, 7:33 PM EDT
Company Description
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
The company was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics
| Country | Switzerland |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Jorge da Silva |
Contact Details
Address: Dorfstrasse 29 Zug, 6300 Switzerland | |
| Phone | 41 415108022 |
| Website | moonlaketx.com |
Stock Details
| Ticker Symbol | MLTX |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001821586 |
| CUSIP Number | 61559X104 |
| ISIN Number | KY61559X1045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Interim Chair of the Board and Chief Executive Officer |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder and Chief Scientific Officer |
| Matthias Bodenstedt | Chief Financial Officer |
| Oliver Daltrop Ph.D. | Chief Operations Officer |
| Carla Bretes | Director of Investor Relations and External Communications |
| Nicolas Mosimann Ph.D. | General Counsel |
| Joana Cortez | Associate Vice-President of Legal and Compliance |
| Tino Anthamatten | Vice President of Marketing, Market Access and Pricing |
| Luciana Marques | Associate Vice-President of Human Resources, People and Culture |
| Nuala Brennan | Chief Clinical Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2026 | ARS | Filing |
| Apr 21, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2026 | 144 | Filing |
| Apr 9, 2026 | 144 | Filing |
| Apr 2, 2026 | SCHEDULE 13D/A | Filing |
| Mar 31, 2026 | 144 | Filing |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 23, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G | Filing |